PhotoCure ASA - Metvix® approved for Bowen's in 22 European countries

29-Nov-2005

PhotoCure ASA announced that Metvix has been approved for Bowen's disease. The new indication is approved in 22 EU/EEA countries through the European Mutual Recognition Procedure. As for other approved dermatological indications, Galderma will be responsible for the marketing and sales of Metvix in markets outside the Nordic region.

Bowen's disease is a non-melanoma skin cancer also known as squamous cell carcinoma (SCC) in situ. It usually appears as a slow-growing red and scaly patch, and is thought to develop partly as a result of long-term sun exposure.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances